Kenvue Receives FDA Approval for Dye-Free and Sugar-Free Labeling for Zyrtec ODT Allergy Medication
Expansion of Dye-Free and Sugar-Free Product Lines
The U.S. Food and Drug Administration (FDA) has approved Kenvue's supplemental application (Supplement S-014) to modify the labeling for its leading allergy medication, Zyrtec (cetirizine hydrochloride) Orally Disintegrating Tablet (ODT) 10mg. This approval allows the addition of "Dye-Free" claims to the adult product and "Dye-Free and Sugar-Free" claims to the children's product, Children's Zyrtec. This change reflects the growing trend of "Clean Labeling," catering to allergy sufferers who are increasingly sensitive to ingredient safety and prefer products free of potentially harmful substances.
Targeting Pediatric and Allergy-Sensitive Consumers
The labeling changes also include improvements to consumer readability, such as bolding the Statement of Identity (SOI) in accordance with 21 CFR 201.61(c). This enhancement aims to provide greater clarity and reassurance, particularly for parents of young children and individuals with chronic allergies who are sensitive to dyes and artificial sugars. The ODT formulation offers convenient administration without water, making it easier to consume. This clean positioning is expected to be a key factor in influencing purchase decisions among parents and caregivers.
Strengthening the Market Position of a Blockbuster Brand
Zyrtec's active ingredient, cetirizine hydrochloride, is a histamine H1 receptor antagonist that effectively blocks allergic reactions. In 2022, Zyrtec generated global sales of approximately USD 2.65 billion, making it a major blockbuster product. Faced with increasing competition from generic drugs following patent expiration, Kenvue is implementing subtle labeling improvements and diversifying formulations to maintain the premium value of its original brand and create barriers to entry.
Surviving in the Competitive OTC Allergy Market
The global OTC allergy market is currently valued at USD 10.1 billion and is expected to reach this level by 2025. Key players in this market include Bayer's Claritin and Sanofi's Allegra, creating a highly competitive landscape. Following its spin-off from Johnson & Johnson (J&J) in 2023, Kenvue has prioritized maximizing the competitiveness of its consumer health division, which is a core revenue driver. Therefore, this labeling update is not merely a cosmetic change but a strategic move to maintain market share in the allergy market, where brand loyalty is high.
The global second-generation antihistamine OTC market is projected to reach USD 10.1 billion by 2025, with strong competitors like Bayer's Claritin and Sanofi's Allegra vying for market share. Zyrtec, already on the market, is a key asset for Kenvue, generating approximately USD 2.65 billion in annual sales. The FDA approval for dye-free and sugar-free labeling allows Kenvue to solidify its position in the niche market of sensitive consumers and pediatric patients. In the short term, this is expected to help defend sales through new packaging marketing, and in the long term, it will help build a differentiated value and regulatory barrier for the original brand against generic products that focus on price competition. This is an important milestone for Kenvue, which spun off from Johnson & Johnson and needs to demonstrate its independent revenue growth capabilities, as it secures both portfolio management efficiency and long-term profitability.
Source: openFDA (api_fda)
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=NDA022578